What is Nektar Therapeutics's other accrued liabilities?

Nektar Therapeutics (NKTR) reported other accrued liabilities of $4.06M in Q1 2026.

How has Nektar Therapeutics's other accrued liabilities changed year-over-year?

Nektar Therapeutics's other accrued liabilities decreased by 65.0% year-over-year, from $11.58M to $4.06M.

What is the long-term trend for Nektar Therapeutics's other accrued liabilities?

Over 5 years (2020 to 2025), Nektar Therapeutics's other accrued liabilities has grown at a -33.5% compound annual growth rate (CAGR), from $20.99M to $2.72M.

Nektar Therapeutics NKTR Other accrued liabilities

Other accrued liabilities at other companies

ImmunityBio, Inc.IBRX

——

Viridian Therapeutics, Inc.VRDN

——

Spyre Therapeutics, Inc.SYRE

——

Immunovant, Inc.IMVT

——

Other financials

Income statement

See full

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

See full

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

See full

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

See full

Market cap$2.19B+1,531%

Profitability

See full

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

See full

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nektar Therapeutics's other accrued liabilities?: Nektar Therapeutics (NKTR) reported other accrued liabilities of $4.06M in Q1 2026.
How has Nektar Therapeutics's other accrued liabilities changed year-over-year?: Nektar Therapeutics's other accrued liabilities decreased by 65.0% year-over-year, from $11.58M to $4.06M.
What is the long-term trend for Nektar Therapeutics's other accrued liabilities?: Over 5 years (2020 to 2025), Nektar Therapeutics's other accrued liabilities has grown at a -33.5% compound annual growth rate (CAGR), from $20.99M to $2.72M.